CorMedix (CRMD) Stock Forecast & Price Target

Cormedix Inc's strategic expansion into total parenteral nutrition (TPN) and improved pricing guidance for its product, DefenCath, indicate potential for significant revenue growth beyond 2027, especially as it targets a broader patient base. The anticipated improvement in pricing and the substantial guidance of $100 million to $140 million in DefenCath sales for 2027 suggest a solid revenue outlook, bolstered by the expected increase in dialysis bundle reimbursement from CMS. Additionally, the Momenta acquisition has not only diversified the company's portfolio but has also introduced considerable revenue contributions and operating synergies, underscoring CorMedix's effective execution and growth potential within the specialty pharmaceutical sector.

Cormedix Inc. is facing a negative outlook primarily due to its 2026 revenue guidance, which falls significantly short of both analyst expectations and consensus estimates. The company's anticipated revenue decline from a pro-forma $400 million in 2025 to a forecasted $300 million-$320 million for 2026, coupled with DefenCath sales projections of $150 million-$170 million, highlights the risk of substantial revenue loss driven by the impending reductions in reimbursement models. Additionally, competitive pressures from generics and concerns over high discontinuation rates related to toxicity and drug interactions pose significant threats to DefenCath's market acceptance, contributing to a decline of approximately 39.3% in the stock year-to-date.